Contact
searchSearch
HMP Global
Login

Myelofibrosis Specialty Channel

Myelofibrosis
Specialty Channel
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Ciro Rinaldi, MD, PhD
Conference Coverage
Elritercept Plus Ruxolitinib Demonstrates Favorable Safety and Strong Efficacy for Patients With Myelofibrosis and Anemia: RESTORE Trial
01/14/2026
Ciro Rinaldi, MD, PhD
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared...
01/14/2026
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Demonstrates Durable Hematocrit Control and Symptom Improvement for Polycythemia Vera: VERIFY Trial
12/17/2025
Andrew Kuykendall
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Quiz
Pelabresib Plus Ruxolitinib for Myelofibrosis
12/01/2025
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination...
12/01/2025
Oncology
News
Ruxolitinib Therapy for Myelofibrosis Demonstrates Comparable Efficacy and Safety Among All Patient Age Groups
12/01/2025
Emily Estrada
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective...
12/01/2025
Oncology
Quiz
Imetelstat Combined With Ruxolitinib for Patients With Myelofibrosis
10/28/2025
True or False: According to results from the IMproveMF trial, imetelstat plus ruxolitinib demonstrated a manageable safety profile and promising clinical activity among patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.
True or False: According to results from the IMproveMF trial, imetelstat plus ruxolitinib demonstrated a manageable safety profile and promising clinical activity among patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.
True or False: According to...
10/28/2025
Oncology
News
Rovadicitinib Shows Efficacy and Manageable Safety for Ruxolitinib-Resistant or Intolerant Myelofibrosis
10/28/2025
Emily Estrada
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with...
10/28/2025
Oncology
Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
Quiz
INCB057643 Therapy for R/R Myelofibrosis
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The...
09/26/2025
Oncology

News

News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
Ciro Rinaldi, MD, PhD
Conference Coverage
Elritercept Plus Ruxolitinib Demonstrates Favorable Safety and Strong Efficacy for Patients With Myelofibrosis and Anemia: RESTORE Trial
01/14/2026
Ciro Rinaldi, MD, PhD
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared...
01/14/2026
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Demonstrates Durable Hematocrit Control and Symptom Improvement for Polycythemia Vera: VERIFY Trial
12/17/2025
Andrew Kuykendall
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
News
Ruxolitinib Therapy for Myelofibrosis Demonstrates Comparable Efficacy and Safety Among All Patient Age Groups
12/01/2025
Emily Estrada
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective...
12/01/2025
Oncology
News
Rovadicitinib Shows Efficacy and Manageable Safety for Ruxolitinib-Resistant or Intolerant Myelofibrosis
10/28/2025
Emily Estrada
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with...
10/28/2025
Oncology
Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
Conference Coverage
BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis
07/14/2025
Emily Estrada
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET...
07/14/2025
Oncology
Conference Coverage
Imetelstat Combined With Ruxolitinib Demonstrates Promising Activity for Patients With Myelofibrosis: IMproveMF Trial
07/14/2025
Emily Estrada
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat...
07/14/2025
Oncology

Interactive Features

Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
Pelabresib Plus Ruxolitinib for Myelofibrosis
12/01/2025
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination...
12/01/2025
Oncology
Quiz
Imetelstat Combined With Ruxolitinib for Patients With Myelofibrosis
10/28/2025
True or False: According to results from the IMproveMF trial, imetelstat plus ruxolitinib demonstrated a manageable safety profile and promising clinical activity among patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.
True or False: According to results from the IMproveMF trial, imetelstat plus ruxolitinib demonstrated a manageable safety profile and promising clinical activity among patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.
True or False: According to...
10/28/2025
Oncology
Quiz
INCB057643 Therapy for R/R Myelofibrosis
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The...
09/26/2025
Oncology
Quiz
Ruxolitinib Combined With Novel Agents for the Treatment of MF
09/12/2025
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to...
09/12/2025
Oncology
Quiz
PXS-5505 for the Treatment of Myelofibrosis
05/23/2025
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
What percentage of patients with relapsed/refractory myelofibrosis treated with novel pan-lysyl oxidase inhibitor PXS-5505 experienced a total symptom score reduction of 20% or more in a phase 1/2a clinical trial?15.3%32%90%62%
What percentage of patients with...
05/23/2025
Oncology
Quiz
Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
Low-Dose Subcutaneous Decitabine Treatment for Patients With MF
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
Efficacy of Zilurgisertib Alone or Combined With Ruxolitinib in Myelofibrosis
08/22/2024
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to...
08/22/2024
Oncology
Quiz
Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment
07/03/2024
07/03/2024
Oncology

Recent News

News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Ruxolitinib Therapy for Myelofibrosis Demonstrates Comparable Efficacy and Safety Among All Patient Age Groups
12/01/2025
Emily Estrada
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective...
12/01/2025
Oncology
News
Rovadicitinib Shows Efficacy and Manageable Safety for Ruxolitinib-Resistant or Intolerant Myelofibrosis
10/28/2025
Emily Estrada
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with...
10/28/2025
Oncology
Conference Coverage
BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis
07/14/2025
Emily Estrada
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET...
07/14/2025
Oncology
Conference Coverage
Imetelstat Combined With Ruxolitinib Demonstrates Promising Activity for Patients With Myelofibrosis: IMproveMF Trial
07/14/2025
Emily Estrada
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat...
07/14/2025
Oncology
News
Combining Ruxolitinib With Novel Agents Shows Promise as Treatment for Patients With Myelofibrosis
05/31/2025
Emily Estrada
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.
The combination of ruxolitinib...
05/31/2025
Oncology
News
PXS-5505 Demonstrates Early Anti-Fibrotic Activity and Tolerability for Patients With R/R Myelofibrosis
05/20/2025
Emily Estrada
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.
For patients with MF who are...
05/20/2025
Oncology
News
Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis
03/17/2025
Emily Estrada
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis...
03/17/2025
Oncology
News
Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis
10/31/2024
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial,...
10/31/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use